leadf
logo-loader
AIM:VRCI

Verici Dx PLC

Receive alerts
Market:
AIM
Market Cap:
£99.22 m
Price
70.00 GBX
Change
-2.10%
52 weeks high
94.95
52 weeks low
29.97

In brief

Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. Its products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.